SEC Company Response from Lyra Therapeutics, Inc. (LYRA) (CIK 0001327273) (LYRA) — Apr 28, 2020
Lyra Therapeutics, Inc. (LYRA) (CIK 0001327273)
Date: April 28, 2020 · CIK: 0001327273 · Accession: 0001193125-20-122823
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236962
Letter
Re: Lyra Therapeutics, Inc.
April 28, 2020
Mr. Paul Fischer
Office of Healthcare and Insurance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1 (as amended) (SEC File No. 333-236962)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Lyra Therapeutics, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., New York City time, on April 30, 2020, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 450 copies of the Preliminary Prospectus dated April 27, 2020 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others.
In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule 15c2-8(b) under the Securities Exchange Act of 1934, as amended.
Very truly yours,
BOFA SECURITIES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 28, 2020 Mr. Paul Fischer Office of Healthcare and Insurance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Lyra Therapeutics, Inc. Registration Statement on Form S-1 (as amended) (SEC File No. 333-236962) Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Lyra Therapeutics, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., New York City time, on April 30, 2020, or as soon thereafter as practicable. Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 450 copies of the Preliminary Prospectus dated April 27, 2020 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others. In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule 15c2-8(b) under the Securities Exchange Act of 1934, as amended. Very truly yours, BOFA SECURITIES, INC. JEFFERIES LLC WILLIAM BLAIR & COMPANY, L.L.C. As Representatives of the several underwriters [SIGNATURE PAGES FOLLOW] BOFA SECURITIES, INC. By: /s/ Michael A.H. Allong Name: Title: Michael A.H. Allong Authorized Signatory JEFFERIES LLC By: /s/ Charlie Glazer Name: Title: Charlie Glazer Managing Director WILLIAM BLAIR & COMPANY, L.L.C. By: /s/ Steve Maletzky Name: Title: Steve Maletzky Partner, Equity Capital Markets As representatives of the several underwriters. cc: Ilir Mujalovic, Partner, Shearman & Sterling LLP [Signature Page to Acceleration Request Letter]